Immunitybio

Immunitybio Tax Expense

The Income Tax Expense of Immunitybio (IBRX) as of Oct 23, 2026 is -135,000.00 USD. In the previous year, Income Tax Expense was 81,000.00 USD — a change of -266.67% (lower).

Tax Expense

-135,000.00USD

YoY

-266.67%

Last updated:

Income Tax Expense of Immunitybio is 2025 -135,000.00 USD. Income Tax Expense of Immunitybio was 2024 81,000.00 USD. It decreases by -266.67% lower compared to the previous year.

The Immunitybio Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2018
-503,000.00 USD
Jan 1, 2019
-97,000.00 USD
Jan 1, 2020
-1.85 M USD
Jan 1, 2021
9,000.00 USD
Jan 1, 2022
34,000.00 USD
Jan 1, 2023
-40,000.00 USD
Jan 1, 2024
81,000.00 USD
Jan 1, 2025
-135,000.00 USD
The Immunitybio Tax Expense history
YEARTax ExpenseYoY
-135,000.00USD-266.67%
81,000.00USD-302.50%
-40,000.00USD-217.65%
34,000.00USD+277.78%
9,000.00USD-100.49%
-1.85 MUSD+1,803.09%
-97,000.00USD-80.72%
-503,000.00USD+2.03%
-493,000.00USD-13.81%
-572,000.00USD+90.03%
-301,000.00USD-30,200.00%
1,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immunitybio Stock analysis

What does Immunitybio do? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunitybio stock

Income Tax Expense of Immunitybio is -135,000.00 USD in 2025.

Income Tax Expense of Immunitybio changed from 81,000.00 USD to -135,000.00 USD, representing a -266.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense Immunitybio since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's Immunitybio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Immunitybio

All Key Metrics — Immunitybio